

SUBJECT INDEX

A

Acetaminophen, 246
Achillea, 547-49
 Adenosine
 erythropoietin production and,
 1, 14-17
 Adenylate cyclase, 179-80,
 183-85, 353
 inhibition
 CB2 cannabinoid receptor
 and, 179, 183-85
 modulation
 CB1 cannabinoid receptor
 and, 179, 183-85
 Adrenergic receptors (ARs),
 351-69
 α_1 , 356-58, 362
 α_2 , 358, 363-65
 agonists, 351
 β , 289-90, 292-96, 298-310,
 358-61, 365-69
 (See also β_2 -Adrenergic
 receptor)
 subfamilies, 351-54
 pharmacology, 352-54
 transgenic investigations,
 351-52, 354-56
 α -AR-mediated cardiac
 hypertrophy and, 356-58
 β_2 -Adrenergic receptor, 289-90,
 292-96, 298-310
 agonist-induced internalization
 of, 303-10
 agonist-specific desensitization
 of G protein-coupled
 receptors and, 290,
 292-305, 307-10
 rhodopsin kinase and, 292
 resensitization, 305-7
 β_2 -Adrenergic receptor kinase,
 292-300
 rhodopsin kinase and, 292-96,
 298-300
 Aging, 45-58
 body composition and, 46-47
 growth hormone-releasing
 hormone and, 46-47
 insulin-like growth factor-I and,
 45-47
 signal transduction and
 neurotoxicity and, 22
 somatotrophic axis and, 46
 Agonist-specific desensitization,
 289-305, 307-10

arrestins and, 289-91, 296-303,
 307-10
 G protein-coupled receptors
 and, 307-10, 289-303
 kinases and, 289-96, 307-10
 rhodopsin phosphorylation
 and, 292-96
 AIDS dementia, 159-71
 anti-retroviral therapy and,
 167-68
 neuronal injury in
 HIV-1 envelope protein
 gp120 and, 159
 NMDA antagonists for
 potential clinical use of,
 168-71
 Alcohol
 breast cancer and, 125-26,
 128
 dependence withdrawal, 28
 teratogenicity, 29-33
 Alendronate, 375-77
 Alzheimer's disease
 apoptosis and, 166-67
 therapeutic use of
 cyclooxygenase-2
 inhibitors for, 112-13
 γ -Aminobutyric acid subtype A
 (See GABA_A)
 AMPA receptors, 321, 326,
 345-46
 diazepam tolerance and, 343-46
 Amphetamine analogs
 serotonergic neurotoxicity
 quinol-thioether metabolites
 and, 237-41
 Anandamide, 179, 185-92
 Anemia
 end-stage renal disease and,
 12-14
 Animal testing, 63-64
 Antihistamine, 413-14
 Apoptosis
 AIDS dementia and, 165-67
 Alzheimer's disease and,
 166-67
 benzene-mediated
 hematotoxicity and, 243
 bisphosphonate and induction
 in osteoclasts, 375, 383-84
 stroke and, 166-67
 Arachidonic acid, 35, 97-114,
 159, 161-64, 185
 AIDS dementia and, 159,
 161-64

cascade, 98
 release, 185
 Arachidonyl ethanolamide,
 185
 Aromatase inhibitors, 124
 Arrestin, 289-91, 296-303,
 307-10
 molecular properties, 299
 rhodopsin and
 activation-recognition
 region, 300-3
 phosphorylation, 297-303
 regulation, 298-303
 nonvisual, 299-300
 visual, 296-303, 307-10
Artemisia, 549-53
 Aryl hydrocarbon (Ah) receptor,
 124
 Aspirin, 99, 102-3, 105
 platelet aggregation and, 102-3
 Asteraceae (Compositae), 539-61
 chemical compounds of
 coumarins, 549, 553
 diterpenes, 549
 flavonoids, 540, 547,
 549-50, 553
 monoterpenes, 549-50, 554
 polyacetylenes, 545-47, 549
 pyrrolizidine alkaloids, 545
 sesquiterpene lactones,
 540-45, 547, 549-50, 554,
 559
 triterpenes, 549
 Atrial natriuretic factor, 357
 Astrocytes
 HIV-1 gp120-activated, 159-60,
 163-65
 Axonopathy, 21
 AZT (See Zidovudine)

B

Baccharis, 553-56
 pharmacology, 554-56
 phytochemistry, 554
 principal medicinal species,
 553-54
 Benzo[a]pyrene
 mammary cancer and, 123-24
 Benzodiazepines, 322, 324,
 337-46, 392, 466-67
 amplification of GABA-gated
 current, 325, 333-34
 classification, 334

- dependence, 321, 342
 drug clearance
 in vitro extrapolation, 466-67
 tolerance, 321, 337-42
 7,8-Benzoflavone, 395, 415
 Bisphosphonates, 375-86
 apoptosis of osteoclasts and, 383-84
 cholesterol biosynthesis pathway and, 375
 filling of the remodeling space in bone and, 379-80
 inhibition of osteoclast formation by, 375, 377-86
 cellular level action, 380-84
 molecular level action, 384-85
 tissue level action, 377-80
 protein tyrosine phosphatases and, 375
 structure-activity relationship, 376-77
 therapeutic uses
 hypercalcemia, 375-76
 osteoporosis, 375-76
 Paget's disease, 375-76
 Body composition, 45-58
 aging and, 46-47
 Bone
 osteoblasts, 377
 osteoclasts, 375, 377-86
 resorption, 375-86
 tumor metastases, 375-76
 Bovine pituitary extract, 67-68
 Bovine serum albumin, 68
 Breast cancer, 121-46
 carcinogen-induced, 123-37
 alcohol, 125-26, 128
 dietary carcinogens, 136-37
 diethylstilbestrol (DES), 125-26
 estrogens, 121, 123, 125-26, 131-33, 138
 "good estrogen-bad estrogen" hypothesis, 131-33
 industrial chemicals, 126-27
 organohalogenes, 129-31
 chemicals protective against, 137-43
 halogenated aromatic hydrocarbons, 138-40
 TCDD, 138-40
 incidence and mortality, 122-23
 lifetime exposure to estrogen and, 121, 123, 138
 (See also Mammary carcinogenesis)
 Bretazenil, 334-36
 5-Bromo-2-deoxyuridine, 92
 tert-Butyl hydroperoxide, 68
C
 Calcitonin, 56-58
 Calcitonin gene-related peptide (CGRP), 103
 Calcium
 homeostasis
 ethanol and, 29
 lead and, 25, 28
 resorption and, 377
 neurotoxic chemicals' effect on, 25
 PCBs and, 33
 lead's mimicry of actions of, 25-28
 signal transduction and, 21, 23-28
 Calcium channels, 201-19
 G protein-linked receptors and, 204-10
 inhibition, 204-10
 localization, 208-10
 mechanism, 205-8
 nerve terminals
 different types, 209
 function, 209-10
 Cancer
 cyclooxygenase-2 inhibitors and treatment for, 111-12
 (See also Breast cancer)
 Cannabinoid, 179-94
 agonists
 anandamide, 185
 arachidonic acid release and, 185
 cannabinoid receptor-independent effects of, 184-85
 MAP-kinase activation and, 184
 nitric oxide production and, 184
 receptors
 CB1, 179-94
 CB2, 179-94
 coupling to signal transduction pathways, 183-85
 inhibition of immune function, 179, 184
 localization, 182
 mechanism of action, 182-83
 Carboxylesterases, 257-80
 carboxy-terminal amino acid sequences, 272-73
 catalytic activity, 266
 distribution, 258-60
 hydrolytic biotransformation and, 257
 isosymes, 268
 regulation, 261-64
 substrates, 260-61
 Catechol estrogens, 135-37
 Celecoxib, 110
 Cell growth
 cyclooxygenase-2 and, 97
 Cell signaling, 21-35
 Chemical-induced stress response, 229
 Chlorinated olefins, 501
 α -Chloroethenolates, 515
 Chromatin
 chemical-induced changes in structure of, 233
 Clearance concept (See Drug clearance, Drug metabolism)
 Cobalt
 early work, 3-5
 erythropoiesis and, 1, 3-6
 Cobalt polycythemia, 1, 3-5
 Corticosterone, 1, 5
 Coumarins, 549, 553
 Cumene hydroperoxide, 69
 Cutaneous toxicity, 65-70
 Draize models, 65-66
 epidermal keratinocyte models, 66-70
 Cyclic AMP, 23, 28
 ethanol metabolism and, 28
 Cyclic GMP, 23
 Cyclic nucleotide metabolism, 23
 Cyclooxygenases 1 and 2 (COX-1, 2), 97-114
 constitutive (COX-1), 97, 99, 101-114
 cell growth and, 97
 differences between biochemical, 99-100
 structural, 100-1
 hyperalgesia and, 105-6
 inducible (COX-2), 97, 99, 101-14
 inflammation and, 97
 selective inhibitors, 107-14
 nerve transmission and, 104-5
 Cyclooxygenase-2 (COX-2)
 inhibitors, 107-14
 therapeutic applications, 111-13
 under development, 110-11
 Cyclosporine, 391, 405-6, 408, 415
 Cysteine
 AIDS dementia and, 159-64
 Cysteine S-conjugate, 501-2, 507-27
 deamination of, 519-20
 fluoroalkene-derived, 515
 β -lyase-dependent activation of, 509-13, 520-27

- N-acylation of, 513-14, 518
nephrotoxicity of, 520-27
novel metabolites of, 514-17
Cysteine S-conjugate β -lyase,
501-2, 509-13, 520-27
nephrotoxicity, 520-27
Cysteinylglycine
dipeptide, 231
S-conjugates, 508
Cytochrome P450
-dependent oxidation, 502
drug biotransformation by,
76-77, 80-83, 85, 90
N-methylation of diazepam and,
464
oxidation of S-conjugates of
haloalkenes and, 518-19
predicting in vivo metabolic
drug clearances using,
474-77
Cytochrome P4503A (CYP3A),
389-418
drug-drug interactions, 412-17
drug metabolism and, 389-418
activity measurement in
vitro, 393-96
activity measurement in vivo,
404-12
cooperativity/allotermism,
395-96
CYP3A4 induction and,
403-12, 417-18
reversible inhibitors of,
396-403, 417-18
Cytokines
AIDS dementia and, 160-63
Cytotoxicity, 63-92
corneal epithelial culture
models, 71-75
epidermal keratinocyte models,
66-70
- D**
- Diacylglycerol, 23, 26
Diazepam, 321, 334-35, 337-46,
464, 488-92
dependence, 342-46
changes in glutamatergic
transmission during,
343-45
N-methylation of, 464
tolerance, 338-42
Didanosine, 167
Diethylstilbestrol (DES), 125-26,
128
7,12-Dimethylbenz[a]anthracene
(DMBA)
mammary cancer and, 123-24,
133-34, 136
- DNA damage
and gene expression, 229-36
growth arrest and, 232-36
iron and ribonucleotides and,
234
quinol-glutathione
conjugate-induced,
232-36
Draize models for cutaneous and
ocular toxicity testing,
65-66, 70, 71, 73-75
Drug clearance
in vitro/in vivo extrapolation,
461-94
benzodiazepines, 466-67
calculation in vitro, 463-64
calculation in vivo, 464-66
drug conjugation and,
477-79
drug-drug interactions and,
482-94
metoprolol, 467-68
nonlinearity in
bioavailability and, 479-81
predictions based on
microsomes and
hepatocytes, 472-74
Drug-drug interactions, 461-62,
482-94
Drug metabolism, 63, 75-85,
257-80, 389-418, 461-94,
540, 560-61
carboxyesterases and, 257-80
cytochrome P450A and,
389-418
in vitro hepatic models, 79-85
in vitro/in vivo extrapolation,
461-94
discrepancies, 468-70
drug conjugation, 477-79
drug-drug interactions and,
482-94
extensive metabolizers,
464-94
metabolic clearance, 461,
463
nonlinearity in
bioavailability and, 479-81
predictions based on
microsomes and
hepatocytes, 472-79
Drug toxicity, 63, 75-92
adsorption, distribution,
metabolism, and excretion,
85
hepatic toxicity studies,
83-85
- E**
- Eicosanoids
AIDS dementia and, 160-63
endogenous cannabimimetic,
185-91
Elephantopus
medicinal uses, 556
pharmacology, 556-57
Endocytosis
clathrin-mediated, 289
Endoplasmic reticulum, 101
End-stage renal disease (ESRD)
anemia and, 12-14
Enzyme induction
cytochrome P4503A and, 389,
403, 417-18
Enzyme inhibition
cytochrome P4503A and,
396-403, 417-18
irreversible, 398
reversible, 396-403
Epinephrine, 351
Erythromycin, 391, 396-99, 403,
405, 411, 414
Erythropoiesis
corticosterone and, 1
end-stage renal disease and,
12-14
glucocorticoids and, 1, 5
hydrocortisone and, 1
regulation of
early work, 4
Erythropoietin (Epo)
cobalt and production of, 1,
3-6
early work, 2-3
gene expression, 1, 14-17
oxygen sensing and signal
transduction pathways and,
1, 14-17
protein kinase C and, 15-16
glucocorticoids and production
of, 5
Esterases
classification, 277-80
Estradiol, 123
Estrogen, 121, 123, 125-26,
131-33, 138
"good estrogen, bad estrogen"
hypothesis, 131-33
lifetime exposure to, 121, 123,
138
Estrone, 123
Ethanol, 21, 25, 28-33
adenylate cyclase and, 28
calcium homeostasis and, 29
cyclic AMP metabolism and,
28-33
neuronal loss from exposure to,
31
phosphatidyl-, 29
phosphoinositide/calcium/PKC
system and, 30-33

- signal transduction systems and, 28-33
- Ethnobotany, 539-61
- natural product remedies of Mexico, 539-61
- (See also Asteraceae (Compositae), Natural products)
- Ethnopharmacology, 539-61
- natural product remedies of Mexico, 539-61
- (See also Asteraceae (Compositae), Natural products)
- N-Ethylmaleimide-sensitive ATPase (See NSF)
- Exocytosis
- vesicle release/exocytosis complex, 202, 212-15
- F**
- Falcarinol, 546-47
- Fatty acid ethanolamide, 179, 185-92
- anandamide, 179, 185-92
- Fetal Alcohol Syndrome, 29
- Flavonoids, 540, 547, 549-50
- Flavin-containing
- monooxygenase, 77-78, 84-85
- Flavin-dependent
- monooxygenases, 518-19
- Fluoxetine, 333
- Folk remedies (See Asteraceae (Compositae), Ethnopharmacology, Natural products)
- Free radicals
- AIDS dementia and, 159-63, 166-67
- apoptotic neuronal cell death and, 166-67
- G**
- G protein-bound receptors, 23
- G protein-coupled receptor, 289-310
- agonist-induced internalization of, 303-10
- agonist-specific desensitization of, 290, 292-305
- arrestins, 289-91, 296-303
- kinases (GRKs), 289-96
- molecular properties, 293
- sequestration, 289, 303-10
- G protein-coupled-receptor superfamily
- adrenergic receptors, 351-69
- G protein-linked receptors, 201, 204-15
- G proteins, 201-15
- GABA_A/C presynaptic receptors, 215-17
- GABA receptors, 321-46
- regulation of subtype diversity, 326-27
- structural diversity, 325, 331-33
- neurosteroids and, 332-33
- structure of subtypes, 327-29
- subtype A, 321-46
- excitation, 324-25
- subtype B, 321, 323-24
- subtype C, 321, 323-24
- Gene targeting
- ectopic adrenergic receptor expression, 356-61
- endogenous adrenergic receptor expression modification, 361-68
- hit and run, 356
- inducible, 356
- knock-in, 356
- knock-out, 362-69
- tissue-specific, 356
- Glucocorticoids
- erythropoiesis and, 1, 5
- Glutamate
- AIDS dementia and, 159, 162
- presynaptic receptors, 215, 219
- γ -Glutamyltransferase, 524
- γ -Glutamyl transpeptidase, 231
- Glutathione (GSH), 230, 501-27
- glutathione-dependent
- bioactivation of haloalkenes, 501-27
- (See also Polyphenolic-glutathione conjugates)
- Glutathione S-conjugate, 501-27
- biosynthesis of, 502-6
- enzymatic processing of, 506-9
- Glutathione-S-transferase, 90
- P-Glycoprotein
- colocalization with cytochrome P45093A, 392
- cGMP phosphodiesterase, 291-92
- rhodopsin phosphorylation and, 292
- gp41, 160, 165
- gp120, 159-71
- gp160, 160
- Growth arrest, 229, 232-36
- and DNA damage, 232-36
- quinol-GSH conjugate-induced, 232-36
- Growth hormone-releasing hormone
- adult-onset deficiency, 47-49
- body composition and, 48
- osteopenia and, 47
- aging and, 46-58
- exercise and muscle strength and, 54-56
- Growth hormone therapy
- monotherapy effects among elderly, 51-54
- short-term effects in elderly, 51-54
- GTP-binding proteins, 23
- Guanylate cyclase, 23
- H**
- Haloalkenes, 501-27
- cysteine S-conjugates of, 501-2, 507-27
- deamination of, 519-20
- β -lyase-dependent activation of, 509-13, 520-27
- N-acetylation of, 513-14, 518
- novel metabolites of, 514-17
- nephrotoxicity of, 520-27
- cytochrome P450 and, 518-19
- flavine-dependent
- monooxygenases and, 518-19
- glutathione-dependent
- bioactivation of, 501-27
- glutathione S-conjugates of
- biosynthesis of, 502-6
- enzymatic processing of, 506-9
- Halogenated aromatic hydrocarbons
- breast cancer and, 138-40
- Heart
- α -adrenergic receptor-mediated cardiac hypertrophy and, 356-58, 362
- β -adrenergic receptors and, 358-61
- chronotropic response, 358
- inotropic response, 358-61
- Helenium*
- chemistry and pharmacology, 557
- ethnobotany, 557
- Hematotoxicity
- benzene-mediated
- apoptosis and, 243-44
- polyphenolic-glutathione conjugates and, 241-44
- Hepatotoxicity, 63, 75-92
- hepatic in vitro model systems, 75-92
- monolayer cell culture, 76
- Herbal remedies (See Asteraceae

- (Compositae), Natural products
- HIV
 - protease inhibitors, 415-17
- HIV-1
 - neuronal injury associated with, 159-71
 - proteins, 120, 159-71
 - macrophage activation by, 159-71
 - (See also AIDS dementia)
- HIV-1-associated cognitive/motor complex (See AIDS dementia)
- Hydrocortisone, 1, 5
- Hydrolytic biotransformation
 - carboxyesterases and, 257-80
- Hydroquinone, 243-45
- 2-Hydroxyestrone
 - breast cancer and, 121, 129, 131-35
- 16 α -Hydroxyestrone
 - breast cancer and, 121, 129, 131-35, 144
- Hyperalgesia, 105-6
- Hypercalcemia
 - alendronate for, 375-76
- Hypertriglyceridemia, 48
- Hypoxia, 1, 3, 14-17
 - erythropoiesis and, 14-17
- Human growth hormone therapy (See Growth hormone therapy)

I

- Ibuprofen, 99, 105, 113
- Imadazenil, 321-22, 335, 338-39, 345-46
- Immediate early genes
 - induction of
 - neurotoxic chemicals and, 25
- Immunosuppressive agents, 414-15
- In vitro model systems, 63-92
 - cutaneous toxicity, 65-70
 - cytotoxicity, 63-92
 - hepatotoxicity, 63, 75-92
 - new chemical entities, 86-92
 - preclinical trials, 87-88
 - ocular toxicity, 63, 65-66, 71-75
- Indomethacin, 99, 105-6
- Inducible gene expression
 - systems, 355
- Inflammation, 97-114
 - cyclooxygenase-1 and prostaglandin synthesis, 101-3
 - cyclooxygenase-2 and
 - fever, 105
 - interleukin-2 and, 101
 - lipopolysaccharides and, 101
 - tumor necrosis factor- α and, 101
- Inositol 1,4,5-trisphosphate, 23
- Insulin resistance, 48
- Insulin-like growth factor-I
 - aging and, 45-47
- Interleukin-6, 73
- Intestine
 - organic cation transport in, 443-47
 - mechanisms of transport across brush border membrane, 446-47
 - structure and function, 443-45
- Ionotropic receptors, 201, 215-19
- Iron
 - cell-cycle arrest and, 234-36

K

- Keratinocytes, 65-70
 - culture models, 66-70
 - normal human epidermal, 69-70
 - proliferation, 69
- Ketoconazole, 397, 399-401, 405-6, 408, 414, 486-88
- Kidney, 1, 6-17, 97, 102, 229-37, 431-38, 520-27
 - end-stage renal disease anemia, 12-14
 - erythropoiesis and, 6-14
 - oxygen delivery and, 12
 - haloalkene-induced
 - nephrotoxicity, 520-27
 - human β -lyase-dependent metabolism and, 524-27
 - inflammation
 - cyclooxygenases and, 97, 102
 - ischemia, 12
 - organic cation carriers and, 433-38
 - mechanism for transport across brush border membrane, 436-38
 - proposed mechanism for transport across basolateral membrane, 438
 - quinol-thioether-mediated toxicity, 229-37
 - structure and function, 434
- Knockout, 362-69

L

- Lamivudine, 167

Lead

- neurotoxicity of, 21, 25-28
 - calcium metabolism and, 25
 - as carcinogen, 26-27
 - cell death and, 27
 - mimicry of calcium actions by, 25-26
 - oxidative stress and, 27
 - protein kinase C activation by, 25-26
 - protein kinase C inhibition by, 26
- Liver, 63, 75-92, 431, 433, 438-43
 - hepatotoxicity
 - hepatic in vitro model systems, 75-92
 - organic cation transport and, 438-43
 - mechanisms of sinusoidal, 441-42
 - mechanisms of transport across canalicular membrane, 443
 - structure and function, 438-40
- Lovastatin, 260

M

- Macrophages
 - brain macrophage-mediated neuronal injury, 161
 - HIV-infected, 159-61
- Mammary carcinogenesis, 121, 123-37
 - chemicals and, 123-37
 - alcohol, 125-26, 128
 - diethylstilbesterol (DES), 125-26
 - estrogens, 121, 123, 125-26, 138
 - risk factors, 123
 - (See also Breast cancer)
- MAP (See Mitogen-activated protein)
- Marijuana, 179-94
 - abuse potential
 - lack of addictive effects, 192
 - therapeutic uses, 179-80
 - historical, 179-80
 - potential, 191-92
- Medroxyprogesterone acetate, 124
- Melatonin biosynthesis, 324
- Mercapturic acids, 513-14, 518
- N-Methyl-D-aspartate (See NMDA)
- Metoprolol
 - drug clearance
 - in vitro/in vivo extrapolation, 467-68

N-Methylnitrosourea
 breast cancer and, 123
 Midazolam, 334, 391, 397, 400,
 408, 410-12, 415
 Mitogen-activated protein (MAP)
 kinase, 23, 184, 208
 cannabinoid agonists and,
 184
 kinase kinase, 23, 35
 MK-966, 110
 Modulation
 chemical and hormonal, 121,
 123-25
 Molecular cloning
 organic cation transporters,
 447-51
 Monoterpenes, 549-50, 554
Montanoa, 557-58
 ethnobotany, 558
 pharmacology, 558
 Myelinopathy, 21

N

Natural products
Achillea, 547-49
Artemisia, 549-53
 Asteraceae (Compositae),
 539-61
Baccharis, 553-56
Elephantopus, 556-57
 feverfew, 544-45
 ginseng, 546-47
Montanoa, 557-58
Packera, 558-59
Parthenium, 559-60
 pharmacology, 539, 541-61
 polyacetylenes and, 545-47
 pyrrolizine alkaloids and, 545
 sesquiterpene lactones, 539-45,
 547, 549-50, 559
Tithonia, 560
 toxicity, 539-40, 544-45,
 559-60
 wormweed, 549
 yarrow, 547-49
 Nephrotoxicity
 haloalkene-induced, 520-27
 covalent adduct formation,
 523
 human β -lyase-dependent
 metabolism and, 524-27
 oxidative stress and, 523
 Neuronopathy, 21
 New chemical entities
 in vitro model systems for
 testing, 86-92
 preclinical trials, 87-88
 Neurosteroids, 332-33
 Neurotoxicity, 21-35, 539-40,

544-45, 559-60
 defined, 21
 ethanol, 21, 25, 28-33
 lead, 21, 25-28
 natural products, 539-40,
 544-45, 559-60
 polychlorinated biphenyls, 21,
 25, 33
 signal transduction and, 21-35
 targets of neurotoxic chemicals,
 22
 trimethyltin, 21, 33-35
 Nicotinic cholinergic presynaptic
 receptors, 215, 217-19
 Nitric oxide, 1, 14-17, 159, 161,
 165, 168-71, 184
 cannabinoids and, 184
 erythropoiesis and, 14-17
 open-channel blockers and,
 168-71
 redox congeners of, 168-71
 synthase, 23-24, 28, 35, 165,
 184
 gene expression; cannabinoid
 receptor and, 184
 HIV gp41 and, 165
 neuroprotective and
 neurotoxic properties, 24
 N-methyl-D-aspartate (See
 NMDA)
 NMDA, 24, 159-71
 AIDS dementia and, 159-71
 antagonists
 potential clinical uses of,
 168-71
 receptors
 HIV-1 and, 159, 161-65,
 167-71
 Nonsteroidal antiinflammatory
 drugs (NSAIDs), 97, 99,
 107-14
 selective cyclooxygenase-2
 inhibitors, 107-14
 Norepinephrine, 351
 Normal human epidermal
 keratinocytes, 69
 NSF (N-ethylmaleimide-sensitive
 ATPase), 202

O

Ocular toxicity, 63, 65-66, 71-75
 corneal epithelial cell culture
 models, 71-75
 Draize models, 65-66, 71,
 73-75
 Omeprazole, 488-92
 Organic cation transporters,
 431-53
 intestine, 443-47

kidney, 433-38
 liver, 431, 433, 438-43
 molecular properties of, 447-51
 clones, 447-51
 Organohalogenes
 breast cancer and, 129-31
 Osteoblasts, 377
 Osteoclasts, 375, 377-86
 bisphosphonate inhibition of
 formation of, 375, 377-86
 osteoporosis and, 375-76, 378
 postmenopausal, 378
 Osteopenia, 47
 Osteoporosis, 45, 375-76, 378
 osteoclasts and
 bisphosphonates and,
 375-76, 378
 Ovulation
 cyclooxygenase-2 and, 97
 Oxidative stress
 cumene hydroperoxide and,
 69
 glutamate-induced
 lead and, 27
 S-conjugate-induced
 cytotoxicity, 523
 tert-butyl hydroperoxide and,
 68
 Oxygen sensing
 erythropoietin production and,
 14-17
 nitric oxide and, 14-17

P

Packera, 558-59
 phytochemistry, 559
 toxicology, 559
 Paget's disease, 375-76, 378
Parthenium, 559-60
 pharmacology, 559-60
 phytochemistry, 559
 Parthenolide, 545
 Peroxynitrate
 neurotoxic effects, 24
 Pharmacokinetic indexes, 461-62
 parameters, 462
 Phosphoinositide metabolism
 PCBs and, 33
 Phospholipase C activation
 thyroid follicular cell
 proliferation and, 357-58
 Phospholipid hydrolysis, 23, 25
 neurotoxic chemical effect on,
 25
 Phospholipid hydrolysis/protein
 kinase C pathway, 21, 26
 Phosphorylation
 G protein-coupled receptor
 kinases and, 289-310

- β_2 -adrenergic receptors and, 289, 292-96
 rhodopsin and, 291-303
 Platelet-activating factor
 AIDS dementia and, 159, 161-63
 Platelet aggregation
 cyclooxygenases and, 102-3
 Polyacetylenes, 545-47, 549
 Poly(ADP-ribose)synthetase, 24
 Polybrominated biphenyls (PBBs)
 mammary carcinogenesis and, 129
 Polychlorinated biphenyls (PCBs), 21, 25, 33, 128-31
 mammary carcinogenesis and, 128-31
 Polynuclear aromatic
 hydrocarbons (PAHs)
 breast cancer and, 123-24, 140-43
 Polyphenolic-glutathione
 conjugates, 229-47
 hematoxicity of, 241-44
 nephrotoxicity of, 231-37
 cellular targets, 231
 chromatin structure and function and, 233
 DNA damage and, 332-36
 growth arrest and DNA damage, 232
 mechanism of action, 231
 reactive oxygen species and, 233-34
 neurotoxicity of, 237-41
 Polyphenols, 229-47
 (See also
 Polyphenolic-glutathione conjugates)
 Potassium channels, 201, 204, 210-12, 214-15
 Prazosin, 353
 Presynaptic inhibition, 204-10
 Presynaptic receptors, 201-19
 ionotropic, 204, 215-19
 GABA_{A/C}, 215-17
 glutamate, 215, 219
 nicotinic cholinergic, 215, 217-19
 metabotropic, 201-15
 G protein-linked, 204-15
 Progestins, 124
 Prostaglandin, 97-114
 cyclooxygenases 1 and 2 and kidney, 97, 102
 platelet aggregation, 102-3
 stomach, 101-2
 uterine contractions in labor and, 103
 cytoprotective response, 236-37
 synthesis
 cyclooxygenase-1 and, 97
 Prostaglandin H₂ synthase, 97
 Protein kinase
 A (PKA), 23
 C (PKC)
 erythropoietin mRNA expression and, 15-17
 ethanol and, 29-33
 lead and activation of, 25-26
 neurotoxic chemical effect on activity of, 25
 PCBs and, 33
 trimethyltin, 33-35
 G (PKG), 23
 Pyramidal assemblies, 321, 323
 Pyramidal neuron
 columnary activity, 323
 Pyrrolizidine alkaloids, 545
- ## Q
- Quinidine, 391, 397
 Quinol-thioethers
 cytotoxicity of, 229-47
 (See also
 Polyphenolic-glutathione conjugates)
 Quinolate
 AIDS dementia and, 159, 161-63
 Quinones, 229-47
- ## R
- Reactive oxygen species
 quinones and, 229-30, 233-34, 241-43
 Receptor tyrosine
 phosphorylation, 23
 Resorption
 inhibitors of
 bisphosphonate, 375-86
 Rhodopsin, 289-303
 agonist-specific desensitization of G protein-coupled receptors, 290-303
 β -adrenergic receptor kinase and, 292-93
 kinase, 291
 phosphorylation sites, 291
 Rifampin, 392, 405-6, 415
- ## S
- Second messenger system, 22-24
 neurotoxicity and, 22
 Selective inhibitors, 97, 107-14
 cyclooxygenase-2 inhibitors, 107-14
 etodolac, 114
 meloxicam, 114
 nimesulide, 114
 Sequestration, 289, 303-10
 Sesquiterpene lactones, 539-45, 547, 549-50, 550
 antiinflammatory effects, 542
 antimigraine activity, 544
 antitumor activity, 542-43
 antiulcer activity, 543
 cardiotonic activity, 543
 contact dermatitis and, 545
 inhibition of transcription factor NF κ B by, 542
 neurotoxicity of, 544
 Sevoflurane, 525
 Signal transduction, 1, 14-17
 erythropoietin mRNA expression and, 14-17
 protein kinase C and, 15-17
 neurotoxicants and, 24-35
 ethanol, 21, 25, 28-33
 lead, 21, 25-28
 polychlorinated biphenyls, 21, 25, 33
 trimethyltin, 21, 33-35
 neurotoxicity and, 21-35
 aging and, 22
 pathways, 22-24
 SNAP-25, 202-3
 Somatopause, 45, 47
 Somatotropic axis
 aging and, 46
 SR144528, 183
 Stavudine, 167
 Stomach
 inflammation
 cyclooxygenases and, 97, 102
 Stroke
 apoptosis
 free radical insults and, 166-67
 NMDA antagonists for potential clinical uses of, 168-71
 Sulfotransferase, 90
 Sulindac, 111-12
 Superoxide anion, 159, 161
 Superoxide anion radical, 230
 Suprachiasmatic nucleus, 324
 Synaptobrevin, 202
 Syaptotagmin, 203
 Syntaxin 1A, 202-4
- ## T
- Terfenadine, 486-88
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD)

- protective effect against breast cancer, 138-40
- Δ^9 -Tetrahydrocannabinol (THC), 179-94
 - arachidonic acid release and, 185
 - synthetic, 180
- Thioketene, 515
- Thomboxane A_2 , 102
- Tithonia*, 560
- Tolbutamide-sulfaphenazole, 485-86
- Transgenic investigation, 351-52, 354-56
- Transmitter release, 201-19
 - exocytosis, 202, 212-15
 - docking, 202
 - G protein-linked receptors and, 204-15
 - priming, 202
 - presynaptic GABA_{A/C} receptors and, 215-17
 - presynaptic glutamate receptors and, 219
- presynaptic nicotinic receptors and, 217-19
- presynaptic receptor activation and
 - calcium channel inhibition and, 201-10
 - potassium channel activation and, 201, 204, 210-12, 214-15
 - vesicle release/exocytosis process and, 201, 212-15
- Triazolam, 486-88
- 2,2,3-Trihalthiiranes, 516, 518
- Trimethyltin
 - neurotoxicity of, 21, 33-35
- Tyrosine kinase, 23, 137
 - breast cancer cell proliferation and, 137

U

- Uridine diphosphate-glucuronyl transferase, 90

W

- Wormweed, 549-53

X

- Xenobiotics
 - cytochrome P450-mediated metabolism of natural products and, 561
 - metabolism and hepatotoxicity of
 - in vitro model systems, 63-92
- Xenoestrogens
 - breast cancer and, 121, 123, 125, 127-38

Z

- Zalcitabine, 167
- Zidovudine (ZDV, AZT), 167

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 34-38

A

Acosta D Jr, 38:63-96
Alexander RW, 36:281-306
Amidon GL, 34:321-41
Anders MW, 38:501-37
Aposhian HV, 37:397-419
Augustine GJ, 36:659-701

B

Bakhle YS, 38:97-120
Barrett JC, 36:573-96
Bellamy WT, 36:161-83
Bennett CF, 36:107-29
Benovic JL, 38:289-319
Benowitz NL, 36:597-613
Bevan JA, 34:173-90
Bilsky EJ, 36:379-401
Black J, 36:1-33
Blaschke TF, 37:451-75
Botting RM, 38:97-120
Boyer JL, 35:541-79
Bray TM, 34:91-115
Brett CM, 38:431-60
Briggs JM, 37:71-90
Briving C, 35:277-305
Burchiel SW, 36:131-59
Burns ME, 36:659-701
Burt SK, 36:545-71

C

Catterall WA, 37:361-96
Chan P-C, 34:41-67
Chang LW, 34:41-67
Chao AC, 35:257-76
Chaudhuri G, 35:165-94;
37:477-515
Chen AY, 34:191-218
Clapham DE, 37:167-203
Collman GW, 36:573-96
Conn PJ, 37:205-37
Correll B, 34:69-89
Corey JL, 34:219-49
Cory-Slechta DA, 35:391-415
Costa E, 38:321-50
Costa LG, 38:21-43
Coyle JT, 36:83-106
Cronstein BN, 35:449-62
Crooke ST, 36:107-29
Croxatto HB, 36:47-81

D

Davila DR, 36:131-59
Davila JC, 38:63-96
Davis B, 35:341-68
DeBello WM, 36:659-701
Dekant W, 38:501-37
De Mey JGR, 35:501-39
Dessauer CW, 36:461-80
Dray A, 36:253-80
Dunham EW, 37:53-69

E

Eaton DL, 34:135-72
Emmerson KS, 34:91-115
Erickson JW, 36:545-71
Esenshade TA, 34:117-33
Evans CJ, 36:379-401
Exton JH, 36:481-509

F

Fan A, 35:341-68
Felder CC, 38:179-200
Felten DL, 35:417-48
Fisher JW, 38:1-20
Fukuto JM, 35:165-94
Furchgott RF, 35:1-27

G

Gallagher EP, 34:135-72
Gardner P, 35:257-76
Giacomini KM, 38:431-60
Gibbs JB, 37:143-66
Gilman AG, 36:461-80
Glass M, 38:179-200
Goldstein A, 37:1-28
Gonzalez FJ, 35:369-90
Griendling KK, 36:281-306
Gudermann T, 36:429-59

H

Halmes NC, 37:91-117
Halpert JR, 35:29-53
Hankinson O, 35:307-40
Harden TK, 35:541-79
Harman AW, 35:129-44

Hefti F, 37:239-67

Heinrich M, 38:539-65
Henrion D, 34:173-90
Hersey S, 35:277-305
Hockerman GH, 37:361-96
Hoffman AR, 38:45-61
Holsapple MP, 36:131-59
Homeister JW, 34:17-40
Hosokawa M, 38:257-88
Howd R, 35:341-68
Howlett AC, 35:607-34
Hoyer PB, 36:307-31
Hsia SMT, 34:41-67
Hsieh L-L, 34:41-67
Huff J, 34:343-72; 36:573-96

I

Ito K, 38:461-99
Iwatsubo T, 38:461-99

J

Joad JP, 37:29-52
Johnson BD, 37:361-96
Jordan VC, 35:195-211

K

Kalkbrenner F, 36:429-59
Kaminski NE, 36:131-59
Kanamitsu S, 38:461-99
Karras JG, 36:131-59
Kastrissios H, 37:451-75
Kobilka BK, 38:351-73
Korzekwa KR, 35:369-90
Krupnick JG, 38:0289-319

L

Lai J, 36:379-401
Lake BG, 35:483-507
Laskin DL, 35:655-77
Lassègue B, 36:281-306
Lau SS, 38:229-55
Lazo JS, 35:635-53
Ledbetter JA, 36:131-59
Lee HJ, 34:321-41
Lemasters JJ, 37:327-38
Le Moal M, 36:359-78
Lester HA, 34:219-49

576 CONTRIBUTING AUTHORS

Li C, 36:185-201
 Liehr JG, 36:203-32
 Lipton SA, 38:159-77
 Liu LF, 34:191-218
 Lucchesi BR, 34:17-40
 Lucier G, 34:343-72
 Lukas SE, 36:333-57

M

Macdonald RL, 35:463-82
 Madden KS, 35:417-48
 Mager S, 34:219-49
 Maines MD, 37:517-54
 Marcus R, 38:45-61
 Marrone TJ, 37:71-90
 Marton LJ, 35:55-91
 Masaki T, 35:235-55
 Maxwell MJ, 35:129-44
 McCammon JA, 37:71-90
 Melchert RB, 38:63-96
 Meyer UA, 37:269-96
 Miljanich GP, 35:707-34
 Miller RJ, 38:201-27
 Minneman KP, 34:117-33
 Mirsalis JC, 35:145-64
 Mombouli J-V, 35:679-705
 Monforte JA, 35:125-44
 Monks TJ, 38:229-55
 Myers MG Jr, 36:615-58

N

Nakajima Y, 38:461-99
 Nathan L, 37:477-515
 Neal RA, 36:35-46
 Neer EJ, 37:167-203
 Nicholas RA, 35:541-79

O

Oguri K, 34:251-79
 Olah ME, 35:581-606
 Oliff A, 37:143-66
 Ondetti MA, 34:1-16
 Ortiz de Montellano BR, 38:539-65

P

Pegg AE, 35:55-91
 Pendino KJ, 35:655-77

Peoples RW, 36:185-201
 Peterson BZ, 37:361-96
 Pettit DL, 36:659-701
 Piazza PV, 36:359-78
 Pin J-P, 37:205-37
 Pinkerton KE, 37:29-52
 Pitt BR, 35:635-53
 Polson JB, 36:403-27
 Porreca F, 36:379-401
 Pratt WB, 37:297-326
 Pumford NR, 37:91-117

Q

Quick MW, 34:219-49

R

Radić Z, 34:281-320
 Ramachandran J, 35:707-34
 Regunathan S, 36:511-44
 Reis DJ, 36:511-44
 Robbins A, 36:47-81
 Robles M, 38:539-65
 Rock DM, 35:463-82
 Rodan GA, 38:375-88
 Rodriguez E, 38:539-65
 Rodriguez RJ, 38:63-96
 Rohrer DK, 38:351-73

S

Sachs G, 35:277-305
 Safe SH, 38:121-58
 Sanders VM, 35:417-48
 Satoh T, 38:257-88
 Schatz AR, 36:131-59
 Schieven GL, 36:131-59
 Schultz G, 36:429-59
 Schweizer FE, 36:659-701
 Shin JM, 35:277-305
 Simonian NA, 36:83-106
 Sipes IG, 36:307-31
 Smits JFM, 35:501-39
 Snyder SH, 35:213-33
 Spitz IM, 36:47-81
 Stiles GL, 35:581-606
 Strada SJ, 36:403-27
 Strosberg AD, 37:421-50
 Struijker-Boudier HAJ, 35:509-39

Stuehr DJ, 37:339-59
 Sugiyama Y, 38:461-99
 Sunahara RK, 36:461-80

T

Taylor P, 34:281-320
 Thummel KE, 38:389-430
 Thurman RG, 37:327-38
 Tritscher A, 34:343-72

U

Urban L, 36:253-80

V

Vanderah TW, 36:379-401
 Vane JR, 38:97-120
 Vanhoutte PM, 35:679-705

W

Wagner JA, 35:257-76
 Wallmark B, 35:277-305
 Wang CC, 35:93-127
 Wei L-N, 37:119-41
 Weight FF, 36:185-201
 Weissmann G, 35:449-62
 West JE, 38:539-65
 White MF, 36:615-58
 Wilkinson GR, 38:389-430
 Winegar RA, 35:145-64
 Witschi H, 37:29-52
 Wolff MS, 36:573-96
 Woosley RL, 36:233-52

Y

Yager JD, 36:203-32
 Yamada H, 34:251-79
 Yoshimura H, 34:251-79

Z

Zaki PA, 36:379-401
 Zanger UM, 37:269-96
 Zhang J, 35:213-33
 Zhang L, 38:431-60
 Zimmerman BG, 37:53-69

CHAPTER TITLES, VOLUMES 34-38

PREFATORY CHAPTER

From Peptides to Peptidases: A Chronicle of Drug Discovery	MA Ondetti	34:1-16
A Research Trail Over Half A Century	RF Furchgott	35:1-27
A Personal View of Pharmacology	J Black	36:1-33
A Career in Toxicology	RA Neal	36:35-46
A Rewarding Research Pathway	A Goldstein	37:1-28
A Quest for Erythropoietin Over Nine Decades	JW Fisher	38:1-20

ALLERGY AND DRUG SENSITIVITY

Catecholamine Influences and Sympathetic Neural Modulation of Immune Responsiveness	KS Madden, VM Sanders, DL Felten	35:417-48
---	----------------------------------	-----------

ANESTHETICS, ANALGESICS, AND ANTIINFLAMMATORY AGENTS

Targets for Antiinflammatory Drugs	BN Cronstein, G Weissmann	35:449-62
Cyclooxygenases 1 and 2	JR Vane, YS Bakhle, RM Botting	38:97-120

ANTIMICROBIAL, ANTIVIRAL, AND ANTIPARASITIC CHEMOTHERAPY

Polyamines as Targets for Therapeutic Intervention	LJ Marton, AE Pegg	35:55-91
Molecular Mechanisms and Therapeutic Approaches to the Treatment of African Trypanosomiasis	CC Wang	35:93-127
Progress in Antisense Oligonucleotide Therapeutics	ST Crooke, CF Bennett	36:107-29
Structural Mechanisms of HIV Drug Resistance	JW Erickson, SK Burt	36:545-71

AUTONOMIC PHARMACOLOGY

α_1 -Adrenergic Receptor Subtypes	KP Minneman, TA Esbenshade	34:117-33
Structure and Function of the β_3 -Adrenergic Receptor	AD Strosberg	37:421-50
Presynaptic Receptors	RJ Miller	38:201-27

BEHAVIORAL AND PSYCHOPHARMACOLOGY

Relationships Between Lead-Induced Learning Impairments and Changes in Dopaminergic, Cholinergic, and Glutamatergic Neurotransmitter System Functions	DA Cory-Slechta	35:391-415
CNS Effects and Abuse Liability of Anabolic-Androgenic Steroids	SE Lukas	36:333-57
Pathophysiological Basis of Vulnerability to Drug Abuse: Role of an Interaction Between Stress, Glucocorticoids, and Dopaminergic Neurons	PV Piazza, M Le Moal	36:359-78

CANCER, CHEMOTHERAPY, AND IMMUNOPHARMACOLOGY

DNA Topoisomerases: Essential Enzymes and Lethal Targets	AY Chen, LF Liu	34:191-218
The ARYL Hydrocarbon Receptor Complex	Oliver Hankinson	35:307-40
Metallothioneins and Cell Death by Anticancer Drugs	JS Lazo, BR Pitt	35:635-53

578 CHAPTER TITLES

Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers	MP Holsapple, JG Karras, JA Ledbetter, GL Schieven, SW Burchiel, DR Davila, AR Schatz, NE Kaminski	36:131-59
The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics	JB Gibbs, A Oliff	37:143-66
Interactions Between Hormones and Chemicals in Breast Cancer	SH Safe	38:121-58
CARDIOVASCULAR PHARMACOLOGY		
Complement Activation and Inhibition in Myocardial Ischemia and Reperfusion Injury	JW Homeister, BR Lucchesi	34:17-40
Pharmacology of Cardiac and Vascular Remodeling	HAI Struijker-Boudier, JFM Smits, JGR De Mey	35:509-39
Angiotensin Receptors and Their Therapeutic Implications	KK Griendling, B Lassègue, RW Alexander	36:281-306
Tissue Renin-Angiotensin Systems: A Site of Drug Action?	BG Zimmerman, EW Dunham	37:53-69
CLINICAL TOXICOLOGY AND DRUG INTERACTIONS		
Cardiac Actions of Antihistamines	RL Woosley	36:233-52
ELECTROLYTES AND MINERAL METABOLISM		
Molecular Strategies for Therapy of Cystic Fibrosis	JA Wagner, AC Chao, P Gardner	35:257-76
ENDOCRINE PHARMACOLOGY		
Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer	VC Jordan	35:195-211
Antiprogestins: Mechanism of Action and Contraceptive Potential	IM Spitz, HB Croxatto, A Robbins	36:47-81
Molecular Mechanisms of Estrogen Carcinogenesis	JD Yager, JG Liehr	36:203-32
Insulin Signal Transduction and the IRS Proteins	MG Myers Jr, MF White	36:615-58
Estrogens and Atherosclerosis	L Nathan, G Chaudhuri	37:477-515
Growth Hormone As Therapy for Older Men and Women	R Marcus, AR Hoffman	38:45-61
In Vitro and In Vivo Drug Interactions Involving Human CYP3A	KE Thummel, GR Wilkinson	38:389-430
ENVIRONMENTAL AND INDUSTRIAL PHARMACOLOGY AND TOXICOLOGY		
Carcinogenicity of TCDD: Experimental, Mechanistic, and Epidemiological Evidence	J Huff, G Lucier, A Tritscher	34:343-72
Risk Assessment of Environmental Chemicals	A Fan, R Howd, B Davis	35:341-68
Macrophages and Inflammatory Mediators in Tissue Injury	DL Laskin, KJ Pendino	35:655-77
Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings	MS Wolff, GW Collman, JC Barrett, J Huff	36:573-96
Enzymatic Methylation of Arsenic Species and Other New Approaches to Arsenic Toxicity	HV Aposhian	37:397-419
GASTROINTESTINAL PHARMACOLOGY		
The Pharmacology of the Gastric Acid Pump: The H ⁺ , K ⁺ ATPase	G Sachs, JM Shin, C Briving, B Wallmark, S Hersey	35:277-305

MECHANISMS OF ACTION OF DRUGS AND CHEMICALS

Putative Mechanisms of Toxicity of 3-Methylindole: From Free Radical to Pneumotoxicosis	TM Bray, KS Emmerson	34:91-115
Mechanisms of Hepatocarcinogenicity of Peroxisome-Proliferating Drugs and Chemicals	BG Lake	35:483-507
P ₂ -Purineric Receptors: Subtype-Associated Signaling Responses and Structure	TK Harden, JL Boyer, RA Nicholas	35:541-79
Pharmacology of Cannabinoid Receptors	AC Howlett	35:607-34
Diversity and Selectivity of Receptor-G Protein Interaction	T Gudermann, F Kalkbrenner, G Schultz	36:429-59
Complexity and Diversity of Mammalian Adenylyl Cyclases	RK Sunahara, CW Dessauer, AG Gilman	36:461-80
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins	JH Exton	36:481-509
Protein Targets of Xenobiotic Reactive Intermediates	NR Pumford, NC Halmes	37:91-117
G Protein Beta-Gamma Subunits	DE Clapham, EJ Neer	37:167-203
Pharmacology of Neurotrophic Factors	F Hefti	37:239-67
Structure-Function Aspects in the Nitric Oxide Synthases	DJ Stuehr	37:339-59
Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels	GH Hockerman, BZ Peterson, BD Johnson, WA Catterall	37:361-96
The Heme Oxygenase System: A Regulator of Second-Messenger Gases	MD Maines	37:517-54
The Role of Receptor Kinases and Arrestins in G Protein-Coupled Receptor Regulation	JG Krupnick, JL Benovic	38:289-319
From GABAA Receptor Diversity Emerges A Unified Vision of GABAergic Inhibition	E Costa	38:321-50
Insights from In Vivo Modification of Adrenergic Receptor Gene Expression	DK Rohrer, BK Kobilka	38:351-73
Mechanism of Action of Biophosphates	GA Rodan	38:375-88

METABOLIC FATE OF DRUGS AND CHEMICALS

Macromolecular Adducts: Biomarkers for Toxicity and Carcinogenesis	LW Chang, SMT Hsia, P-C Chan, L-L Hsieh	34:41-67
Regiochemistry of Cytochrome P450 Isozymes	K Oguri, H Yamada, H Yoshimura	34:251-79
Structural Basis of Selective Cytochrome P450 Inhibition	JR Halpert	35:29-53
Cytochromes P450 Expression Systems	FJ Gonzalez, KR Korzekwa	35:369-90
P-Glycoproteins and Multidrug Resistance	WT Bellamy	36:161-83
Structure-Based Drug Design: Computational Advances	TJ Marrone, JM Briggs, JA McCammon	37:71-90
Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism	UA Meyer, UM Zanger	37:269-96
The Pharmacology and Toxicology of Polyphenolic-Glutathione Conjugates	TJ Monks, SS Lau	38:229-55
The Mammalian Carboxylesterases: From Molecules to Functions	T Satoh, M Hosokawa	38:257-88
Glutathione-Dependent Bioactivation of Haloalkenes	MW Anders, W Dekant	38:501-37

580 CHAPTER TITLES

MISCELLANEOUS

- | | | |
|---|--|------------|
| The Role of the hsp90-Based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling via MAP Kinase | WB Pratt | 37:297-326 |
| Medication Compliance as a Feature in Drug Development | H Kastrissios, TF Blaschke | 37:451-75 |
| Ethnopharmacology of Mexican Asteraceae (Compositae) | M Heinrich, M Robles, JE West, BR Ortiz de Montellano, E Rodriguez | 38:539-65 |

NEUROMUSCULAR PHARMACOLOGY

- | | | |
|---|--------------------------|-----------|
| Reperfusion Injury After Liver Preservation for Transplantation | JJ Lemasters, RG Thurman | 37:327-38 |
|---|--------------------------|-----------|

NEUROPHARMACOLOGY AND NEUROCHEMISTRY

- | | | |
|--|---|------------|
| β -Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease | B Cordell | 34:69-89 |
| Permeation Properties of Neurotransmitter Transporters | HA Lester, S Mager, MW Quick, JL Corey | 34:219-49 |
| The Cholinesterases: From Genes to Proteins | P Taylor, Z Radić | 34:281-320 |
| Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition | JM Fukuto, G Chaudhuri | 35:165-94 |
| Nitric Oxide in the Nervous System | J Zhang, SH Snyder | 35:213-33 |
| Polyamine Regulation of <i>N</i> -Methyl-D-Aspartate Receptor Channels | DM Rock, RL Macdonald | 35:463-82 |
| Adenosine Receptor Subtypes: Characterization and Therapeutic Regulation | ME Olah, GL Stiles | 35:581-606 |
| Oxidative Stress in Neurodegenerative Diseases | NA Simonian, JT Coyle | 36:83-106 |
| Lipid vs Protein Theories of Alcohol Action in the Nervous System | RW Peoples, C Li, FF Weight | 36:185-201 |
| New Pharmacological Strategies for Pain Relief | A Dray, L Urban | 36:253-80 |
| Opioid Receptor Types and Subtypes: The δ Receptor as a Model | PA Zaki, EJ Bilsky, TW Vanderah, J Lai, CJ Evans, F Porreca | 36:379-401 |
| Imidazoline Receptors and Their Endogenous Ligands | S Regunathan, DJ Reis | 36:511-44 |
| Pharmacology of Nicotine: Addiction and Therapeutics | NL Benowitz | 36:597-613 |
| Exocytosis: Proteins and Perturbations | GJ Augustine, ME Burns, WM DeBello, DL Pettit, FE Schweizer | 36:659-701 |
| Pharmacology and Functions of Metabotropic Glutamate Receptors | PJ Conn, J-P Pin | 37:205-37 |
| Signal Transduction in Environmental Neurotoxicity | LG Costa | 38:21-43 |
| Neuronal Injury Associated with HIV-1: Approaches to Treatment | SA Lipton | 38:159-77 |
| Cannabinoid Receptors and Their Endogenous Agonists | CC Felder, M Glass | 38:179-200 |

PERINATAL AND DEVELOPMENTAL PHARMACOLOGY

- | | | |
|---|----------------------------------|----------|
| The Toxicology of Environmental Tobacco Smoke | H Witschi, JP Joad, KE Pinkerton | 37:29-52 |
|---|----------------------------------|----------|

PHARMACOKINETICS, DRUG ABSORPTION, AND EXCRETION

- | | | |
|--|---------------------------------|-----------|
| Absorption of Peptide and Peptidomimetic Drugs | GL Amidon, HJ Lee | 34:321-41 |
| Role of Organic Cation Transporters in Drug Absorption and Elimination | L Zhang, CM Brett, KM Giacomini | 38:431-60 |

PHARMACOLOGICALLY ACTIVE NATURAL SUBSTANCES

- | | | |
|---|------------------------------|-----------|
| Mechanisms of Aflatoxin Carcinogenesis | DL Eaton, EP Gallagher | 34:135-72 |
| Antagonists of Neuronal Calcium Channels:
Structure, Function, and Therapeutic
Implications | GP Miljanich, J Ramachandran | 35:707-34 |

REPRODUCTION AND FERTILITY

- | | | |
|--|--------------------|-----------|
| Assessment of Follicle Destruction in
Chemical-Induced Ovarian Toxicity | PB Hoyer, IG Sipes | 36:307-31 |
|--|--------------------|-----------|

SMOOTH MUSCLE PHARMACOLOGY

- | | | |
|--|----------------------------|------------|
| Pharmacological Implications of the
Flow-Dependence of Vascular Smooth
Muscle Tone | JA Bevan, D Henrion | 34:173-90 |
| Possible Role of Endothelin in Endothelial
Regulation of Vascular Tone | T Masaki | 35:235-55 |
| Kinins and Endothelial Control of Vascular
Smooth Muscle | J-V Mombouli, PM Vanhoutte | 35:679-705 |
| Cyclic Nucleotide Phosphodiesterases and
Vascular Smooth Muscle | JB Polson, SJ Strada | 36:403-27 |

TECHNIQUES

- | | | |
|--|---|-----------|
| An Evaluation of the Role of Calcium in Cell
Injury | AW Harman, MJ Maxwell | 35:129-44 |
| Transgenic Animal Models for Detection of In
Vivo Mutations | JC Mirsalis, JA Monforte,
RA Winegar | 35:145-64 |
| Transgenic Animals as New Approaches in
Pharmacological Studies | L-N Wei | 37:119-41 |
| Predictive Value of In Vitro Model Systems in
Toxicology | JC Davila, RJ Rodriguez,
RB Melchert, D Acosta Jr. | 38:63-96 |
| Quantitative Prediction of In Vivo Drug
Clearance and Drug Interactions from In Vitro
Data on Metabolism, and Together with
Binding and Transport | K Ito, T Iwatsubo, S Kanamitsu,
Y Nakajima, Y Sugiyama | 38:461-99 |

the 1990s, the number of people in the UK who are aged 65 and over has increased by 1.5 million (1990–1999) (Office of National Statistics 2000).

There is a growing awareness of the need to address the health care needs of the ageing population. The Department of Health (1999) has set out a vision for the future of health care for older people, and the National Institute for Clinical Excellence (NICE) (2000) has published guidance on the management of older people with chronic conditions. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people. The Department of Health (2000) has also published a strategy for the future of health care for older people, which sets out a vision for the future of health care for older people, and a strategy for the future of health care for older people.

